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Key Clinical Message
Refractory empyema occasionally reflects hidden malignant disease. We presented
a rare case of rapidly progressive malignant mesothelioma of the pleura (MPM)
mimicking empyema. Physicians should be aware of MPM when patients with
empyema are refractory to the standard treatment, and PET-CT may be helpful in
establishing a precise diagnosis in such cases.
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Introduction
Malignant pleural mesothelioma (MPM) has one of the
poorest prognosis among respiratory diseases. Although
the age-standardized incidence rates in males and females
during 1999–2001 were only 12.5 to 3 per 100,000 per-
son-years in Japan, respectively, MPM is still a major
public health problem, as it is related to environmental
and occupational asbestos exposure [1, 2]. An interna-
tionally conducted epidemiological survey estimated that
the incidence peak of MPM in European countries will be
reached between 2015 and 2020 [3]. To diagnose MPM,
thoracoscopic biopsy is often needed; however, it is diffi-
cult to perform such an invasive procedure in patients of
unstable clinical condition. Additionally, the clinical man-
ifestations of MPM are usually nonspecific. Therefore,
MPM is likely to be misdiagnosed as either tuberculous
pleurisy or metastatic pleural lung cancer [4]. Here, we
present the case of a patient diagnosed and treated for
pulmonary empyema, but was instead revealed by autopsy
to have sarcomatoid MPM.
Case Report
An 82-year-old man presenting with prolonged cough and
dyspnea visited our hospital. Chest radiography (Fig. 1A)
revealed a massive loculated pleural effusion in right tho-
rax. Neither pleural thickening nor pleural plaque was
revealed following a computed tomography (CT) scan of
the chest. The blood examination indicated a slight eleva-
tion of white blood cells, measured at 13,600/µL; C-reactive
protein (CRP) was measured at 14.8 mg/dL, and lactate
dehydrogenase (LDH) at 289 IU/L. Tumor markers were
within normal levels (carcinoembryonic antigen [CEA] at
2.7 ng/mL, squamous cell carcinoma-related antigen at
1.3 ng/mL, and sialyl Lewis-x antigen at 27.5 IU/mL). We
conducted an interferon-gamma-release assay, and it was
negative. A chest drainage tube was immediately placed
into the right thorax, and a total of 1200 mL of purulent
pleural effusion was released. The specific gravity, LDH,
and glucose levels of the pleural effusion were 1.029,
2140 IU/L, and 118 mg/dL, respectively. Neither adenosine
deaminase (24.4 U/L) nor hyaluronic acid (43,800 ng/mL)
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was found to be elevated. No pathogens were cultured from
the pleural effusion, and no malignant cells were detected.
He had no obvious history of environmental or occupa-
tional asbestos exposure. A species of Corynebacterium was
cultured from his pleural effusion. His initial diagnosis was
pulmonary empyema. In addition to the drainage, an
empiric course of antibiotic treatment with ampicillin/sul-
bactam was administered. During the first week, his clinical
symptoms improved; however, two weeks after initial ther-
apy, he developed an inflammatory reaction and high fever,
and his condition declined rapidly. A chest CT scan
revealed a remaining and enlarging loculated pleural effu-
sion (Fig. 1B and C). Another chest drainage tube was
placed in the upper right thorax, but sufficient drainage
was not achieved because of the hyperviscosity of the
pleural effusion. The resistance of his condition to
treatment with antibiotics and drainage therapy led us to
consider the possibility of a malignant disease. A thoraco-
scopic lung/pleural biopsy was not performed because of
his unstable vital signs. Although empyema with midline
shift on chest radiography also suggested malignant disease,
repeated cytologic analyses of his pleural effusion indicated
no evidence of malignancy and elevation of CEA was
absent in both serum and pleural effusion. As an
alternative, positron emission tomography–computed
tomography (PET-CT) was conducted, and intensive
fluorodeoxyglucose (FDG) accumulation was detected
throughout his entire right pleura (Fig. 2A and B). These
findings strongly suggested the presence of malignant
mesothelioma.
A further examination was not performed due to his
severe respiratory failure. He died one month after his
initial visit to our hospital.
Outcome and follow-up
An autopsy revealed large regions of necrotic tissue
throughout the entire right thorax (Fig. 3A). Dissecting




Figure 1. Chest radiography (A) at initial visit showed a massive
pleural effusion on the right thorax. A Loculated pleural effusion was
confirmed on the upper right thorax. Chest computed tomography (B,
C) performed 2 weeks after admission confirmed massive enlarging
loculated effusions. Two chest drainage tubes were separately
inserted into the upper and lower right thorax.
(A)
(B)
Figure 2. A positron emission tomography–computed tomography
scan (A, B) revealed a high integration of fluorodeoxyglucose along
the entire circumference of the pleura.
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of tumors. Histopathologic analysis demonstrated a dense
tumor tissue characterized by spindle-shaped cells with
atypical nuclei (Fig. 3B). Immunohistopathology revealed
extensive positivity for AE1/AE3 and CAM2.5 (Fig. 3C
and D). The focal regions of positivity for desmin and
myoglobin were also revealed (Fig. 3E and F), which indi-
cated localized ectopic rhabdomyosarcoma. These findings
comprehensively suggested that the patient suffered from
sarcomatoid MPM.
Discussion
Here, we presented a case of sarcomatoid MPM that was
characterized by several unique and interesting features.
First, the present case was mimicking pulmonary empyema.
The pleural effusion associated with MPM usually has
diverse properties, such as the presence of exudative or
blood effusion, but it typically does not contain pus. Mul-
tilocular effusions are typically more indicative of empyema
rather than MPM. Furthermore, our case lacked character-
istic radiologic findings of MPM, such as pleural thickening
and pleural plaque [5].
Second, the disease progression of the patient was quite
rapid. MPM can be divided into three histologic types:
the epithelioid type, sarcomatoid type, and mixed type
[6]. The sarcomatoid type is reported to encompass 4.9%
to 25% of MPM cases [2, 7]. MPM usually progresses
slowly over several decades following exposure to asbes-
tos. MPM is a progressive disease, and the median sur-
vival time is approximately 10 months [2]; however,
extremely rapid progression of the disease, such as in the
case presented, is uncommon.
A case report similar to ours has been previously pub-




Figure 3. Autopsy specimens revealed large regions of necrotic tissue throughout the right lung (A). The dissected surface of the right lung
indicated a massive progression of tumors. Histopathological analysis revealed a dense tumor characterized by spindle-shaped cells with atypical
nuclei (B, H-E stain, 9100). Immunohistopathologic analysis demonstrated positive staining for AE1/AE3 (C, 9400) and for Cam5.2 (D, 9400).
Focal positive staining for desmin (E, 9400) and myoglobin (F, 9400) was also observed.
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treated as an empyema due to the presence of characteris-
tic clinical findings, but both cases were refractory to the
standard therapy that is used for empyema. In the previ-
ous case, a thoracoscopic examination was performed;
however, the procedure focused entirely on the dissection
of the empyema, and a histologic examination was not
concurrently conducted. The diagnosis of sarcomatoid
MPM was made over a course of months; by contrast,
thoracoscopy was not performed in our case due to the
unstable vital signs of the patient. As an alternative, PET-
CT was performed in our case, and the intensive FDG
accumulation throughout the patient’s entire right pleura
suggested the diagnosis of MPM. It has been reported
that PET-CT is a sensitive method for identifying MPM
[9]. It has also been reported that the presence of high
FDG uptake in the pleura in conjunction with scant FDG
uptake in the surrounding empyema is a distinct sign of
pleural malignant disease [10, 11]. When we are faced
with a patient presenting with refractory empyema, we
should consider the possibility that the patient might have
MPM; further investigation of patient’s condition using
PET-CT may also be warranted.
Conclusion
We presented a rare case of rapidly progressive sarcoma-
toid MPM mimicking pulmonary empyema. Physicians
should be aware of MPM when patients with empyema are
refractory to the standard treatment, and PET-CT may be
helpful in establishing a precise diagnosis in such cases.
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